China sets more funds for HIV research

    Updated: 2011-09-15 07:28

    By Shan Juan (China Daily)

      Comments() Print Mail Large Medium  Small 分享按鈕 0

    BANGKOK - China invested more than $18 million in HIV vaccine research and development in 2010, becoming the third largest contributor globally, after the United States and the European Union, according to a report endorsed by UNAIDS.

    Internationally, HIV vaccine research and development (R&D) funding stood at $859 million last year, $9 million less than 2009, while China increased its spending by nearly $4 million over the same period, said the global report issued jointly by international organizations including AIDS Vaccine Advocacy Coalition (AVAC) and Intentional AIDS Vaccine Initiative.

    "The long-term nature of vaccine research will require sustained investments globally and more developing countries like China are expected to shoulder more responsibilities," Kevin Fisher, the coalition's policy director said at the 2011 AIDS Vaccine Conference, which opened on Tuesday.

    Unfortunately, overall global funding for HIV R&D has flattened out since 2000 and some early supporters, such as Canada and Sweden, have cut back, said the report. In the EU, a major contributor, funding has declined by 23 per cent since 2007.

    In contrast, the Chinese government has pledged to further boost funding for HIV vaccine development by at least 20 percent in five years, according to Shao Yiming, director of the virology and immunology department of the National Center for AIDS/STD Control and Prevention.

    Currently, China has four major HIV vaccine candidates under development on the mainland, all financed by the government.

    "Compared with many developed countries like the US, which has dozens of HIV vaccine candidates under development, China needs more to have a better chance of success," Shao said.

    His team is now waiting for approval from China's drug authorities to enter the second phase of the clinical trial for their HIV vaccine candidate, Tiantan.

    Usually a vaccine has to undergo three phases of human trials before being licensed for use, experts said. The first two phases mainly test its safety and the third mainly its efficacy.

    By May, 24 HIV vaccine candidates had entered the human trial stages across the world, including Tiantan, which is the only one from China to have reached that point.

    Shao urged the Chinese government to regularly increase funding for vaccine development, particularly when some attention has been diverted to new prevention measures with proven efficacy.

    "An effective and affordable vaccine is unanimously recognized as the ultimate weapon against HIV/AIDS worldwide," he said.

    "The funding and human resources for vaccine R&D in China should be diversified and stakeholders like charities and industry should join in the effort."

    Currently, all such studies on the mainland are funded and organized by the government, he said.

    Half of the resources come from non-public sectors like pharmaceutical companies and philanthropic organizations, according to Shao.

    As well, Kevin Fisher called on the Chinese government to be more transparent and to collaborate with international researchers in HIV vaccine development.

    He said the Chinese authorities were usually reluctant to share relevant information, such as the amount of investment, with international stakeholders.

    欧美中文字幕在线| 国产午夜片无码区在线播放| 狠狠噜天天噜日日噜无码| 最近2019年免费中文字幕高清| 日韩精品无码熟人妻视频| 青娱乐在线国产中文字幕免費資訊 | 亚洲 欧美 中文 在线 视频| 无码午夜成人1000部免费视频| 最近中文2019字幕第二页| 中文无码vs无码人妻 | 亚洲中文久久精品无码ww16| 色综合久久中文综合网| 亚洲Aⅴ无码一区二区二三区软件 亚洲?V无码乱码国产精品 | 无码人妻少妇久久中文字幕蜜桃| 中文字幕视频在线| 亚洲va中文字幕无码久久不卡| 草草久久久无码国产专区| 无码H肉动漫在线观看| 中文无码久久精品| 在线看片福利无码网址| www日韩中文字幕在线看| 中文字幕亚洲免费无线观看日本| 一本之道高清无码视频| 天堂亚洲国产中文在线 | 亚洲中文久久精品无码| 日韩亚洲不卡在线视频中文字幕在线观看 | 亚洲av无码成人精品区在线播放| 狠狠躁天天躁无码中文字幕图| 无码AV岛国片在线播放| 无码国产精品一区二区免费16 | 国产av无码专区亚洲av果冻传媒| 最近中文字幕大全免费视频| 视频二区中文字幕| 最新版天堂中文在线| 最近中文国语字幕在线播放| 亚洲日韩在线中文字幕第一页| 惠民福利中文字幕人妻无码乱精品| 中文字幕在线视频网| 免费a级毛片无码a∨免费软件 | 无码专区AAAAAA免费视频| 亚洲AV无码专区国产乱码4SE|